Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Steppe Cement shares surge after strong Q1 growth

(Sharecast News) - Shares in Steppe Cement surged on Tuesday after the Kazakhstani cement manufacturer announced a big jump in sales in the first quarter and a healthy increase in market share. For the three months to 31 March, Steppe sold 276,217 tonnes of comment for KZT6.47bn ($12.7m), compared with 175,383 tonnes for KAZT3.79bn ($8.4m) the year before.

This represents a 57% jump in volumes and a 71% increase in revenues generated in Kazakhstani tenge.

The strong start to the year saw its share of the market grow to 13.5%, up from 11.5% a year earlier.

Meanwhile, the average price per tonne for delivered cement was KZT23,404, up 9% on the year before.

Production of clinker - the solid, lumpy material produced in the cement manufacturing process - was 14% higher than the previous year in the first quarter, meaning Steppe is "well positioned to take advantage of the traditionally busier summer months", it said.

However, looking ahead, the company maintained a "conservative" outlook for the rest of 2025: "Despite significant growth in the first quarter, rising inflation and global developments may have a considerable impact on the investment climate in Kazakhstan's construction sector. The company currently estimates Kazakhstan's cement market demand for 2025 to be approximately 12 million tonnes, similar to 2024."

Steppe's share price was up 14.3% at 16p in afternoon trade in London.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.